Abstract Protein kinase CK2, a ubiquitous serine/threonine kinase in control of a variety of crucial cellular functions, is composed of catalytic a-and a 0 -subunits and non-catalytic b-subunits which form holoenzymes such as CK2(ab) 2 , CK2aa 0 b 2 , or CK2(a 0 b) 2 . In addition, there is ample evidence for the occurrence of the individual subunits beside the holoenzyme. While the CK2 subunits are well analyzed on the protein level, only little is known about the regulation of their transcription. The existence of multiple forms of CK2 subunits raised the question about a mutual regulation of their expression. Here we defined two 5 0 -upstream regions of the CK2a and the CK2b genes, respectively, as sequences with promoter activities. We found that CK2a and CK2a 0 stimulated the expression of the reporter constructs whereas, CK2b was inactive. Using chromatin immunoprecipitation assays, we were unable to detect binding of endogenous CK2 subunits to these promoter sequences in vivo. However, it turned out that inhibition of the kinase activity of CK2 attenuated the promoter activity indicating that CK2a and CK2a 0 might regulate their gene expression indirectly by phosphorylation reactions. Thus, we have shown here (i) that under normal physiological conditions CK2 does not bind to CK2 promoter regions and (ii) that the CK2 kinase activity is implicated in the regulation of its own expression.
Introduction
Protein kinase CK2, formerly known as casein kinase 2, is known for more than 50 years [1] . It is a ubiquitously expressed protein kinase which phosphorylates more than 500 different substrates and this number is steadily increasing. This large number of different substrates indicates that CK2 is implicated in numerous cellular processes including regulation of cell proliferation and survival [2, 3] . An elevated expression level and an increased kinase activity for CK2 were found in tumor cells compared to normal, non-transformed cells [4] . This later observation made CK2 an interesting pharmacological target for the treatment of cancer [5, 6] .
Thornburg and Lindell [7] first described CK2 as a multi-subunit protein kinase that is generated by the association of two a-and/or a 0 -subunits with a dimer of the b-subunit. This structure and composition of CK2 was quickly confirmed by Dahmus and Natzle [8] . Stigare, however reported in 1993, that CK2a was tightly bound to nuclear structures in the absence of its b-subunit [9] indicating that the CK2 subunits exist not only in the holoenzyme but also in a free form or individually associated with other cellular proteins or structures. An unbalanced expression of CK2a and CK2b subunits was later on described for different mammalian tissues [10] [11] [12] . CK2a is not only active as a phosphotransferase in the holoenzyme but also in the absence of CK2b. Loss of CK2b is lethal [13] which may imply that some aspects of the CK2b functions are not based on its interaction with the CK2a subunits. Live cell fluorescence imaging revealed that CK2a and CK2b show an independent movement within a eukaryotic cell. Furthermore, CK2a and CK2b enter the nucleus independently [14] . Unlike CK2b, nuclear CK2a can be exported back to the cytosol. Finally, a large excess of CK2b is synthesized compared to CK2a and the noncomplexed CK2b protein is rapidly degraded [15] . The human genome contains two CK2a loci, at chromosomes 20p13 and 11p15, where primarily the locus on chromosome 20 is transcriptionally active. The locus on chromosome 11 was thought to be a permanently silent pseudogene [16] [17] [18] [19] . However, it turned out that this intronless CK2a gene is expressed in some cancer cells but only minimally expressed in normal cells [20] . It therefore still has to be clarified whether or not it is a protein-coding gene or a processed pseudogene.
The CK2a 0 gene has been mapped to chromosome 16p13.2-13.3 [21] , whereas the CK2b gene has been mapped to chromosome 6p21.3 [17] . The genomic structures of the different CK2 genes in various organisms have been characterized [22] [23] [24] [25] [26] [27] [28] . Due to the fact that the individual CK2 subunits assemble into the holoenzyme, which is composed of two CK2a or CK2a 0 and two CK2b subunits and that the subunits exist outside of the holoenzyme, it was an obvious question whether the expression of the subunits might be coordinately regulated. The promoter regions for the different CK2 genes were characterized and furthermore it was shown, that CK2a appears to function as a trans-activating factor for the CK2b gene transcription [29] . Electrophoretic Mobility Shift Assays (EMSA) suggested a binding of CK2a to the CK2b promoter. Overexpression of CK2a resulted in an elevated level of CK2b protein which might suggest that CK2a stimulate the transcription of CK2b although other mechanisms are possible. Previously, it has been shown that CK2 activity is down-regulated at the transcriptional level in both senescent lung fibroblasts and in aged rat tissues and it has been proposed that DNA methylation may be involved in inactivating CK2 in senescent cells [30] . Possibly, promoter methylation may be used as a general mechanism for regulation of CK2 expression. However, so far there is no indication for direct methylation of the CK2a and CK2b promoters [31] .
While the cellular stoichiometry of the catalytic and the regulatory subunits are well characterized, the situation at the transcriptional level is less clear. Thus, we decided to analyze the influence of CK2a, CK2a 0 , and CK2b on the CK2a and CK2b promoters. In contrast to previous studies, we used DNA sequences of at least 1.3 kb directly upstream of the translational start sites instead of small DNA fragments. We found that the CK2 catalytic subunits stimulated the expression of both, the CK2a and CK2b genes. However, using chromatin immunoprecipitation assays, we found no direct binding of CK2a and CK2b to these promoter DNAs. Instead, transcription was attenuated after inhibition of the CK2 kinase activity by two different CK2 inhibitors indicating that the enzyme activity is necessary for transcriptional regulation of the CK2 subunits.
Materials and methods
Cell culture and drug treatment HCT116 cells are human colon carcinoma cells, which were previously characterized in detail [32] and were a kind gift from Vogelstein [33] . Cells were cultured in McCoy 0 s 5A Modified Medium with GlutaMAX TM -I (Life Technologies, Darmstadt, Germany) containing 10 % fetal calf serum (FCS; PAA, Pasching, Austria) at 37°C and 5 % CO 2 in a humidified atmosphere. For selective inhibition of endogenous CK2 kinase activity, HCT116 cells were treated with CK2 inhibitors CX-4945 (1 or 10 lM in DMSO, Selleckchem, München, Germany) or TF (50 lM in DMSO, a kind gift from Joachim José [34] ) for 24 h or with DMSO as solvent control.
CK2 protein kinase assay
To study CK2 kinase activity in cell extracts, 30 lg of total protein was mixed with 20 ll of kinase buffer [50 mM TrisHCl, pH 7.5, 100 mM NaCl, 10 mM MgCl 2 , 1 mM dithiothreitol (DTT)]. After addition of 30 ll of CK2 assay mix (25 mM Tris-HCl, pH 8.5, 150 mM NaCl, 5 mM MgCl 2 , 1 mM DTT, 50 lM ATP, 0.19 mM CK2-specific substrate peptide with the sequence RRRDDDSDDD, 10 lCi (0.37 MBq) [c-32 P]ATP), the reaction mix was incubated at 37°C for 5 min and then stopped on ice. The sample was pipetted onto Whatman-P81 cation-exchange paper and washed three times with 85 mM phosphoric acid for 5 min, followed by washing with ethanol. The dried filter paper was counted for Č erenkov radiation in a scintillation counter (Liquid Scintillation Analyzer 190S AB/LA; CanberraPackard GmbH, Dreieich, Germany).
Plasmids and cloning of promoter constructs
Firefly luciferase reporter vector (pGL4.10) and Renilla luciferase reporter control vector (pGL4.70) were from Promega (Mannheim, Germany). The human CK2a (PI) promoter fragment, containing 1329 nucleotides upstream of the start codon, was obtained by PCR amplification with the primers CK2a-hum-prom-ATG-1329-for: 5 0 -ATG AAG CTT GTG CGG TGG CTC ACA TCT GTG-3 0 ;
CK2a-hum-prom-ATG-rev: 5 0 -ATG CCA TGG GCA TGT CAG ACA GGT TGG CGG AC-3 0 and cloned (HindIII/ NcoI) into pGL4.10. The human CK2a (PII) promoter fragment, containing 1920 nucleotides upstream of the first exon, was obtained by PCR amplification with the primers CK2a-hum-prom-up-for: 5 0 -ATG AGA TCT AGG TAA GCT CCA CCA GTG AGC-3 0 ; CK2a-hum-prom-up-rev: 5 0 -ATG AAG CTT GCT CTC CCC TCT GCT CAC AC-3 0 and cloned (BglII/HindIII) into pGL4.10. The human CK2b promoter fragment, containing 1896 nucleotides upstream of the start codon, was obtained by PCR amplification with the primers CK2b-hum-prom-for: 5 0 -AGA AGA TCT CGG GGA GAG TCT C-3 0 ; CK2b-hum-prom-rev: 5 0 -ATG CCA TGG AGC TGC TCA TCT TCA CGT CAG-3 0 and cloned (BglII/NcoI) into pGL4.10. All sequences of cloned fragments were confirmed by DNA sequencing.
The p3xFLAG-CMV-7.1-basic vector was from SigmaAldrich (München, Germany). To generate the expression plasmids p3xFLAG-CMV-7.1-CK2a and p3xFLAG-CMV-7.1-CK2a 0 , the human cDNA of CK2a (1176 nucleotides) and CK2a 0 (1050 nucleotides) were cloned into p3xFLAG-CMV-7.1-basic with HindIII and BamHI. The sequences of both DNA constructs were verified by sequencing. The expression plasmids of the kinase-dead mutants CK2amut (K68M) and CK2a 0 mut (K69M) were a generous gift from Litchfield [35] . Both cDNAs were subcloned in p3xFLAG-CMV-7.1-basic vector as described earlier [36] . The probasin promoter construct was a kind gift from Thomas Kietzmann and Elitsa Dimova. For the luciferase reporter assay, HCT116 cells were seeded into a 24-well plate (40,000 cells per well) in a total volume of 0.5 ml/well of cell culture medium and cultured overnight. Cells were then transfected using a total of 1 lg of plasmid DNA by using Turbofect Ò transfection reagent (transfection mixture per well: 0.3 lg of promoter reporter plasmid, 0.2 lg of Renilla luciferase control plasmid, 0.5 lg of indicated expression plasmid, 2 ll Turbofect Ò transfection reagent and 200 ll cell culture medium without FCS).
For western blot analysis, HCT116 cells were seeded into a 6-well plate (800,000 cells per well) in a total volume of 2 ml/ well of cell culture medium. Cells were cultured overnight and were then transfected using Turbofect Ò transfection reagent using a total of 4 lg of plasmid DNA (transfection mixture per well: 1 lg of promoter reporter plasmid, 1 lg of Renilla luciferase control plasmid, 2 lg of indicated expression plasmid, 6 ll of Turbofect Ò transfection reagent and 400 ll of cell culture medium without FCS).
For measuring luciferase activity, cells were collected at given time points after transfection by lysing in passive lysis buffer (PLB, Promega) and measured with the DualLuciferase Reporter Assay System (Promega) following the manufacturer's recommendations. Relative light units (RLUs) were calculated by normalizing firefly luciferase activity to Renilla luciferase activity.
For western blot analysis, cell lysates were centrifuged at 13,0009g to remove cell debris. The protein content was determined with the Roti Ò -Quant kit (Roth, Karlsruhe, Germany). Protein extracts were immediately used for western blot analysis or stored at -20°C.
SDS-polyacrylamide gel electrophoresis and western blot analysis
Proteins were analyzed by SDS-polyacrylamide gel electrophoresis following standard protocols [37] . In brief, 50 lg of proteins per lane were dissolved in sample buffer (130 mM Tris-HCl, pH 6.8, 0.02 % bromophenol blue (w/v), 10 % b-mercaptoethanol, 20 % glycerol (v/v), and 4 % SDS (w/v)) and separated on a 12.5 % SDS-polyacrylamide gel in electrophoresis buffer (25 mM Tris-HCl, pH 8.8, 192 mM glycine, and 3.5 mM SDS) and transferred onto a PVDF membrane (Roche Diagnostics, Mannheim, Germany) in a buffer containing 20 mM Tris-HCl, 150 mM glycine, pH 8.3. The membrane was blocked with 5 % dry milk in PBS with 0.1 % of Tween20 (PBST) for 1 h and then incubated with appropriate primary antibodies diluted in PBST with 1 % dry milk (incubation buffer). For the detection of protein kinase CK2, we used rabbit anti-peptide serum #26 (a-subunit) [38] , rabbit polyclonal anti-CK2b serum and the monoclonal antibody anti-FLAGM2 (F3165, SigmaAldrich). We used an a-tubulin-specific mouse monoclonal antibody (clone DM1A, Sigma-Aldrich) as loading control. All the antibodies were diluted 1:1,000 in incubation buffer and incubated with the membrane for 1 h at room temperature or overnight at 4°C. The membrane was washed twice with incubation buffer and incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody (goat anti-rabbit IgG, 1:30,000 or goat anti-mouse IgG 1:30,000 in incubation buffer; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at room temperature. Chemiluminescence signals were visualized by the ECL Lumilight system of Roche Diagnostics according to the manufacturer's instructions.
Chromatin immunoprecipitations (ChIP)
ChIP assays were performed with minor modifications as described earlier [39] . 1 % of crosslinked and sonicated chromatin of HCT116 cells was taken as input and kept at 4°C overnight instead of precipitation. DNA from approximately 2.5 9 10 6 cells was used in each immunoprecipitation with the following antibodies: anti-CK2a, rabbit anti-peptide serum #26 [38] ; anti-CK2b, rabbit polyclonal antibody against full length protein; anti-SP1 rabbit polyclonal antibody (07-645, Merck Millipore, Darmstadt, Germany); normal rabbit IgG (sc-2027, Santa Cruz Biotechnology), used as a control for non-specific signals. For the precipitations, 1 lg of normal rabbit IgG, 4 lg of antibody anti-SP1, and 20 ll of anti-peptide sera were utilized. After addition of the antibodies, the samples were incubated at 4°C overnight on a rotating wheel. Twenty-five microlitre of Protein G Dynabead suspension (Life Technologies) were used to purify antibodybound protein-DNA complexes. The beads were washed seven times with wash buffer (0.25 M LiCl, 0.5 % (v/v) Nonidet P-40, 0.5 % (w/v) sodium deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, pH 8.0) before the bound complexes were eluted twice, each with 100 ll elution buffer (50 mM Tris-HCl, pH 8.0, 0.1 % (w/v) SDS, 10 mM EDTA) at 28°C. After elution, formaldehyde crosslinks were reversed and DNA was precipitated and purified. qPCR was then carried out using the Brilliant III Ultra-Fast SYBR 
Statistical analysis
Results of luciferase reporter assays in Fig. 2a, d were expressed as mean ± standard deviation (SD) of at least eight independent experiments. Statistical analysis of the data was performed using the Two-sample t-test (Origin software; OriginLab Corporation, Northampton, MA, USA). p \ 0.05 was considered significant.
Results
The relevant promoter regions of CK2 subunit genes reside upstream of their respective transcriptional start sites For the analysis of transcriptional regulation of CK2 subunit expression, relevant promoter regions have to be identified. Especially the organization of the CK2a gene with the first untranslated exon located over 35 kb upstream of its translational start site emerges the question, which DNA region harbors the relevant promoter region of this gene. Therefore, in contrast to previous studies [29] , we amplified extended DNA regions of over 1.3 kb directly upstream of the CK2a start codon (PI, Fig. 1a ) as well as nearly 2 kb immediately upstream of the distant transcriptional start sites of the CK2a gene (PII, Fig. 1a ) by PCR and cloned both potential CK2a promoter fragments into luciferase reporter vector pGL4.10. For analysis of the transcriptional regulation of the CK2b gene, we amplified and cloned a DNA fragment encompassing 1.9 kb upstream of the CK2b start codon, including the transcriptional start site, the first untranslated exon 1 as well as intron 2 of the CK2b gene (Fig. 1b) .
HCT116 cells were transfected with the reporter constructs together with a Renilla luciferase plasmid to calculate the transfection efficiency. As a further control, we also transfected the vector DNA without the putative promoter regions into HCT116 cells. Cells were extracted and the luciferase activity was measured as described in ''Materials and methods'' section. The luciferase reporter gene assays reveal clearly that only those DNA sequences directly upstream of the transcriptional start site of CK2a and CK2b genes, PII and CK2b, exhibit very strong promoter activities (Fig. 1c) . The sequence immediately upstream of the translational start site (PI) showed no promoter activity. Therefore, no further experiments were carried out with this inactive reporter construct. For simplicity, the active promoter construct CK2a (PII) is hereinafter called CK2a promoter. In the next step, we analyzed whether the reporter assay is dose dependent. Therefore, 50, 100, or 300 ng of the promoter constructs were transfected into HCT116 cells. The following reporter assay revealed that the luciferase activity increased with increasing concentrations of the reporter constructs (Fig. 1d) . The relative luciferase light units were displayed relative to the vector control.
Ectopic expression of catalytic CK2 subunits but not of their kinase-dead mutants leads to a modest but significant increase in promoter activity of CK2a and CK2b promoters Regulation of CK2a and CK2b gene expressions at the transcriptional level is not well characterized to date. More than 20 years ago CK2a was found to bind to calf thymus DNA and to k-phage DNA [40] . Later on, the CK2a protein was found to complex with the CK2b gene promoter [29] . Therefore, we decided to analyze whether the catalytic subunits of CK2 (CK2a or CK2a 0 ) might influence the expression of CK2 subunits. To this end, we transiently transfected cells with an active reporter construct (CK2a-luc and CK2b-luc, respectively), together with plasmids coding for CK2a, CK2a 0 or an empty vector control. Our data clearly demonstrated a modest but significant increase in CK2a as well as CK2b promoter activities after ectopic expression of CK2a (Fig. 2a) and CK2a 0 subunits (Fig. 2d) . These trans-activating effects observed 24 h after transfection increased further when incubation time was extended to 48 h. No further increase was observed 72 h after transfection (Fig. 2a, d ). Western blot analysis with aliquots of transfected cells demonstrated protein expression of FLAG-tagged CK2a and CK2a 0 subunits, respectively (Fig. 2a, d ) demonstrating that similar amounts of CK2a or CK2a 0 were used for the determination of the luciferase activity. In contrast, ectopic expression of kinase-inactive mutants of CK2a(K68M) or CK2a 0 (K69M) [35] significantly influenced neither CK2a nor CK2b promoter activities (Fig. 2c, f) , although cotransfection of expression plasmids for these mutants lead to a clear increase in the respective protein level (Fig. 2c, f) . As a further control, we analyzed effects of ectopic expression of FLAG-tagged CK2a and CK2a 0 subunits towards (i) the probasin promoter and (ii) the empty reporter plasmid pGL4.10. We found that expression of CK2a or CK2a 0 had no influence, neither on the empty reporter plasmid (pGL4.10) nor on the probasin promoter (Fig. 2b, e) .
As CK2a and CK2b form heterotetramers, we additionally analyzed promoter activities after co-expression of both CK2a/CK2a 0 and CK2b subunits, alone and in combination. As expected, ectopic expression of CK2b alone did not change CK2 promoter activities significantly (Fig. 3a) , whereas CK2a and CK2a 0 led to a moderate but significant increase of both promoter activities (Fig. 3b, c) . Surprisingly, neither CK2a nor CK2b promoter activities increased further after combined overexpression of CK2a and CK2b subunits (Fig. 3b) . Also combined expression of CK2a 0 and CK2b subunits, did not significantly change CK2a promoter activity (Fig. 3c) . Solely, the activity of the CK2b promoter seemed to be slightly increased after combined CK2a 0 and CK2b expression. Taken together, these data indicate that obviously monomeric CK2 rather than the holoenzyme is responsible for the observed autoregulation of CK2 expression. Transcriptional regulation of CK2 subunits expression through CK2a and CK2b is not dependent on their direct binding to promoter DNA As expression of the CK2a subunit leads to an increase in promoter activities of their respective genes, we wondered whether the CK2a subunit might influence CK2a and CK2b transcription through direct binding to their promoter regions. To analyze direct binding of CK2 subunits to the respective CK2 promoter regions in vivo, we performed chromatin immunoprecipitation (ChIP) experiments. It was previously shown that the general transcription factor SP1 binds to a minimal fragment of the CK2a promoter [41] as well as to the CK2b promoter [42] . Therefore, serving as a positive control in our ChIP assay, endogenous SP1 was found to bind to CK2a as well as CK2b promoter regions in vivo (Fig. 4) . In contrast to SP1, neither endogenous CK2a nor CK2b were able to bind CK2a or CK2b promoter DNA in vivo (Fig. 4) . As a negative control, none of these proteins bind to the testisspecific glyceraldehyde-3-phosphate dehydrogenase promoter (GAPDHS), indicating specific binding in the ChIP assays.
Promoter activities of CK2a and CK2b decrease after inhibition of CK2 kinase activity After exclusion of a direct binding of CK2 subunits to their respective promoter regions, we next asked whether the CK2 kinase activity might have an influence on the transcriptional regulation of CK2a and/or CK2b. To address this question, we transfected HCT116 cells with CK2a and CK2b promoter constructs, subsequently, we blocked endogenous CK2 kinase activity through treatment of the cells with CX-4945, a highly selective inhibitor of CK2 kinase activity. It was shown earlier that sensitivity of cancer cell lines to CX-4945 can vary in a broad range [43] . Therefore, in early experiments we treated HCT116 cells with CX-4945 at different concentrations. Only about 65 % of endogenous CK2 kinase activity of HCT116 cells was blocked after treatment with 1 lM of CX-4945, while treatment of these cells with 10 lM of CX-4945 lead to a nearly complete inhibition of endogenous CK2 kinase activity (Fig. 5b) . We therefore decided to use this CK2 inhibitor at a concentration of 10 lM for inhibition of endogenous CK2 kinase activity. As shown in Fig. 5 about 90 % of endogenous CK2 kinase activity was inhibited after treatment of the HCT116 cells with CX-4945 for 24 h (Fig. 5b) . Furthermore, promoter activities of both CK2a and CK2b promoters were repressed in a dose-dependent manner when endogenous CK2 kinase activity was blocked by the selective CK2 inhibitor CX-4945 (Fig. 5a) .
We further treated HCT116 cells with the structurally unrelated CK2 inhibitor TF [34] . At a concentration of 50 lM TF, we found a decrease in endogenous CK2 kinase activity (Fig. 5e ) comparable to the effect of treatment of the cells with 1 lM CX-4945 (Fig. 5b) . Analyses of CK2 promoter activities (Fig. 5d ) and endogenous CK2 mRNA levels after treatment of the cells with TF (Fig. 5f ), promoter activities measured after cotransfection with the vector control were set to 100 %. Means and standard deviations of three independent experiments are shown. *p \ 0.05, **p \ 0.01, ***p \ 0.001. Western blot analyses of cotransfected HCT116 cells were analyzed in parallel and illustrate clear overexpression of FLAG-tagged wild-type CK2b (a). Anti-FLAG antibody was used at a dilution of 1:1,000. Detection of a-tubulin protein by anti-a-tubulin antibody, at a dilution of 1:1,000, was used as a loading control for the extracts in the experiments revealed similar effects as they are induced by 1 lM CX-4945 (Fig. 5a, c) .
Taken together, our data suggest, that CK2a and CK2a 0 influence the expression of CK2a and CK2b, on the transcriptional level not directly by binding to DNA but by the CK2 kinase activity.
Discussion
The regulation of protein kinase CK2 has been the subject of intensive research [44, 45] . Previous work mainly focused on regulation of CK2 kinase activity and protein level and led to the conviction, that CK2 is a ubiquitously expressed, constitutively active kinase [46, 47] . However, the CK2 kinase has also been shown to be a crucial constituent of tightly regulated cellular processes [48] [49] [50] . In addition, the expression and/or the activity of individual CK2 subunits seem to be controlled independently but very precisely. This is evidenced inter alia by differences in the relative expression of individual CK2 transcripts during embryonic development as well as by differential expression of CK2 genes in diverse tissues of adult animals [48, 51, 52] . For example, CK2a is widely expressed in all human tissues while CK2a 0 is predominantly expressed in testis and in brain [10, 53] . Furthermore, the expression of CK2b protein differs from that of CK2a and CK2a 0 proteins, suggesting variations in the composition of the tetrameric CK2 holoenzyme in different tissues [54] . The underlying mechanisms for such differences may comprise transcriptional and translational regulation, posttranslational modifications, and stabilization of CK2 subunits at both mRNA and protein level, as well as the subcellular localization of individual CK2 subunits or CK2 holoenzyme.
Little is known to date about the transcriptional regulation of CK2 subunit expression. In an early report, it was shown that CK2 bound to calf thymus DNA and to k-phage DNA [40] . Blotting experiments showed that DNA bound CK2 through its a-subunits. Pyerin et al. [29, 41, 42, 55] characterized DNA sequences upstream of the transcriptional start sites as promoter regions and used different fragments for promoter studies. Using gel mobility shiftassays as well as DNaseI footprinting, CK2a was found to bind to fragments within these promoter sequences but only when CK2a was expressed in excess of CK2b [29] .
To address this issue, we decided to analyze transcriptional regulation of individual CK2 subunits with the focus on potential self-regulatory mechanisms. Previous studies suggested that relevant promoter regions of CK2a, CK2b genes are located within a few hundred base pairs upstream of the transcription start sites. In most of the experiments, even smaller DNA fragments were used for the analysis of transcriptional control [18, 56] . Interestingly, the CK2a gene is organized with the first exon located over 35 kb upstream of the second exon, which harbors the start codon. Several eukaryotic genes are known with a first Fig. 1a, b . As negative controls, either no antibody (w/o antibody) or a non-targeting rabbit antibody (IgG) was used. Analysis of SP1-binding served as a positive control. All signals are given relative to the input. c The GAPDHS promoter served as negative control for SP1 binding large intron, which harbor regulatory elements influencing gene expression [57] [58] [59] . Furthermore, it is described, that most regulatory elements are located in the 5 0 -flanking region of the ATG start codon of genes [60, 61] . We therefore were wondered, if there were essential regulatory elements located directly upstream of the ATG start codon of human CK2a gene, which may contribute to expression control of CK2a subunit. In order to gain further insights into the transcriptional regulation of the CK2a gene, we cloned a potential promoter region proximate to the CK2a start codon, encompassing over 1.3 kb (Fig. 1a, PI) . We however found, that this proximal promoter region does not harbor any promoter activity (Fig. 1c) . In contrast, analysis of a distal promoter construct, containing 1.9 kb upstream of the CK2a transcriptional start site (Fig. 1a, PII) , reveals a very strong promoter activity (Fig. 1c) . We therefore used this distal CK2a promoter construct for subsequent investigations of CK2a transcriptional regulation.
The organization of the CK2b gene resemble that of CK2a concerning location of the start codon within exon 2 (Fig. 1b) . The first untranslated exon however, is separated by a smaller intron, encompassing only 612 bp. In order to include all potential regulatory sequences, we cloned a DNA fragment of 1.9 kb upstream of the start codon of the CK2b gene. This fragment includes complete sequences of intron 1 and untranslated exon 1 as well as the 5 0 -flanking region upstream of CK2b transcriptional start site. Both, the 1.3 kb upstream sequence of the CK2a gene and the 1.9 kb upstream sequence of the CK2b gene showed a dose-dependent promoter activity.
We found that the catalytic subunits of CK2 led to a moderate but significant trans-activation of both CK2a and CK2b promoters, whereas the b-subunit did not show any significant transcriptional activation (Figs. 2, 3 ). According to our data from ChIP analyses, neither CK2a nor CK2b bound to promoter sequences (Fig. 4) which seems to be different from the previous reports. However, Robitzki et al. [29] only observed binding of CK2a to a promoter element when CK2a was present in excess of CK2b. In ChIP assays, we precipitated only endogenous CK2 subunits without any forced overexpression. Under these conditions CK2a is complexed completely to CK2b. Thus, we conclude from our results that CK2a and CK2b do not function as transcription factors for their own expression. This conclusion was supported by the observation that inhibition of the kinase activity by two structurally unrelated inhibitors led to an attenuation of the transcriptional activation of the CK2a and CK2b genes and to a decrease in CK2 mRNA levels (Fig. 5) . Probably due to the wellknown high protein stability of CK2 subunits ( [15, 62] and our own observation), we were not able to detect this effect on protein level (data not shown). Remarkable, inhibition of over 90 % of endogenous CK2 kinase activity by CX-4945 (Fig. 5b ) only leads to downregulation of promoter activities of about 50 % (CK2a) or 25 % (CK2b), respectively (Fig. 5a ). This discrepancy may be explained by basal control mechanisms of CK2 promoter activities. CK2a as well as CK2b promoters were basically influenced by several transcription factors, including SP1, ETS1, and NFjB [50, 51, 57] . Obviously, these transcription factors generate basal promoter activities of both promoters, while CK2 kinase activity itself seems to be responsible for the respective fine regulation and required for full promoter activities. Therefore, our data suggest that CK2 regulates its transcription by phosphorylation of transcription factors. One of the candidates may be SP1 which was shown in this study to bind to both promoter elements and which was shown to be a substrate for CK2 [63, 64] . However, it was shown that phosphorylation of SP1 by CK2 led to a decrease in the DNA-binding activity of SP1 [63] . Thus, we conclude that SP1 is not the transcription factor which is activated by CK2 for the regulation of the CK2 gene expression. Ets1 is another transcription factor which is supposed to bind to the CK2a promoter [56] . So far, it is not known whether Ets1 is a substrate for CK2. However, there may be a number of other transcription factors implicated in the regulation of CK2 gene expression which are not known so far. Work to identify these factors is currently in progress.
We have shown here that under normal physiological conditions CK2 does not bind to CK2 promoter regions and that the CK2 kinase activity is implicated in the regulation of CK2a and CK2b gene expressions.
